Skip to content

Study · Randomized controlled trial · n = 283 · 2020

10 results

Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China.

Sun Y, Xie L, Xu T, Jakobsen JS, Han W, Sørensen PS, Wang X

Asian journal of urology23 Sept 2019Cited by 22 (Europe PMC)

PMID32742930 (opens in a new tab)PMCIDPMC7385516 (opens in a new tab)DOI10.1016/j.ajur.2019.09.003 (opens in a new tab)PepBankPUB-32742930
Read at sourcePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In Chinese men with prostate cancer, degarelix was non-inferior to goserelin for maintaining castrate testosterone, with a cumulative probability difference of 3.6%.

    In plain wordsIn Chinese men with prostate cancer, degarelix was non-inferior to goserelin for maintaining castrate testosterone.

    Peptide
    Degarelix
    Outcome
    Not applicableMaintenance of castrate testosterone
    Study

    n = 283

    Comparator
    Goserelin
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    240/80 mg monthly · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    Probability difference
    3.6%
    95% CI -1.5% to 8.7%; Day 28-364

    Source sentences

    Summary
    The difference in cumulative probability of maintaining castrate levels from Day 28-364 was 3.6% (95% CI:-1.5%, 8.7%), demonstrating non-inferiority of degarelix.
    2 context sentences
    Summary · context
    This is an open-label, multi-centre study in which men aged ≥18 years were randomised in a 1:1 ratio to once-a-month subcutaneous injection of either degarelix (240/80 mg) or goserelin (3.6 mg) for 12 months.
    Summary · context
    Baseline demographics and disease characteristics were similar between degarelix (n=142) and goserelin (n=141) treatment arms.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In Chinese men with prostate cancer, goserelin was the comparator for demonstrated degarelix non-inferiority in maintaining castrate testosterone.

    In plain wordsIn Chinese men with prostate cancer, degarelix was non-inferior to goserelin for maintaining castrate testosterone.

    Peptide
    Goserelin
    Outcome
    Not applicableMaintenance of castrate testosterone
    Study

    n = 283

    Comparator
    Degarelix
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3.6 mg monthly · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    Probability difference
    3.6%
    degarelix minus goserelin; 95% CI -1.5% to 8.7%

    Source sentences

    Summary
    The difference in cumulative probability of maintaining castrate levels from Day 28-364 was 3.6% (95% CI:-1.5%, 8.7%), demonstrating non-inferiority of degarelix.
    2 context sentences
    Summary · context
    This is an open-label, multi-centre study in which men aged ≥18 years were randomised in a 1:1 ratio to once-a-month subcutaneous injection of either degarelix (240/80 mg) or goserelin (3.6 mg) for 12 months.
    Summary · context
    Baseline demographics and disease characteristics were similar between degarelix (n=142) and goserelin (n=141) treatment arms.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In Chinese men with prostate cancer, PSA progression-free survival at Day 364 was higher with degarelix than goserelin.

    In plain wordsIn Chinese men with prostate cancer, PSA progression-free survival was higher with degarelix than goserelin.

    Peptide
    Degarelix
    Outcome
    IncreasePSA progression-free survival
    Study

    n = 283

    Comparator
    Goserelin
    Analysis
    Secondary
    Outcome group
    Tumor growth · Cancer
    Studied dose
    240/80 mg monthly · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    PSA-PFS
    82.3%
    degarelix; 95% CI 74.7% to 87.7%
    PSA-PFS
    71.7%
    goserelin; 95% CI 63.2% to 78.5%; p=0.038

    Source sentences

    Summary
    The cumulative probability of PSA-PFS at Day 364 was higher for degarelix (82.3%, 95% CI: 74.7%, 87.7%) versus goserelin (71.7%, 95% CI: 63.2%, 78.5%, p=0.038).
    2 context sentences
    Summary · context
    This is an open-label, multi-centre study in which men aged ≥18 years were randomised in a 1:1 ratio to once-a-month subcutaneous injection of either degarelix (240/80 mg) or goserelin (3.6 mg) for 12 months.
    Summary · context
    Baseline demographics and disease characteristics were similar between degarelix (n=142) and goserelin (n=141) treatment arms.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In Chinese men with prostate cancer, PSA progression-free survival at Day 364 was lower with goserelin than degarelix.

    In plain wordsIn Chinese men with prostate cancer, PSA progression-free survival was lower with goserelin than degarelix.

    Peptide
    Goserelin
    Outcome
    DecreasePSA progression-free survival
    Study

    n = 283

    Comparator
    Degarelix
    Analysis
    Secondary
    Outcome group
    Tumor growth · Cancer
    Studied dose
    3.6 mg monthly · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    PSA-PFS
    71.7%
    goserelin; 95% CI 63.2% to 78.5%
    PSA-PFS
    82.3%
    degarelix; 95% CI 74.7% to 87.7%; p=0.038

    Source sentences

    Summary
    The cumulative probability of PSA-PFS at Day 364 was higher for degarelix (82.3%, 95% CI: 74.7%, 87.7%) versus goserelin (71.7%, 95% CI: 63.2%, 78.5%, p=0.038).
    2 context sentences
    Summary · context
    This is an open-label, multi-centre study in which men aged ≥18 years were randomised in a 1:1 ratio to once-a-month subcutaneous injection of either degarelix (240/80 mg) or goserelin (3.6 mg) for 12 months.
    Summary · context
    Baseline demographics and disease characteristics were similar between degarelix (n=142) and goserelin (n=141) treatment arms.
  5. 05HumanRandomized controlled trialSafety outcome

    In Chinese men with prostate cancer, adverse events were similar with degarelix and goserelin except for injection site reactions.

    In plain wordsIn Chinese men with prostate cancer, adverse events were similar with degarelix and goserelin except for injection site reactions.

    Peptide
    Degarelix
    Outcome
    No significant changeAdverse events
    Study

    n = 283

    Comparator
    Goserelin
    Outcome group
    Adverse events · Whole body
    Studied dose
    240/80 mg monthly · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Adverse events (AEs) were similar between treatment arms, except for more injection site reactions with degarelix versus goserelin.
    2 context sentences
    Summary · context
    This is an open-label, multi-centre study in which men aged ≥18 years were randomised in a 1:1 ratio to once-a-month subcutaneous injection of either degarelix (240/80 mg) or goserelin (3.6 mg) for 12 months.
    Summary · context
    Baseline demographics and disease characteristics were similar between degarelix (n=142) and goserelin (n=141) treatment arms.
  6. 06HumanRandomized controlled trialSafety outcome

    In Chinese men with prostate cancer, adverse events were similar with goserelin and degarelix except for injection site reactions.

    In plain wordsIn Chinese men with prostate cancer, adverse events were similar with goserelin and degarelix except for injection site reactions.

    Peptide
    Goserelin
    Outcome
    No significant changeAdverse events
    Study

    n = 283

    Comparator
    Degarelix
    Outcome group
    Adverse events · Whole body
    Studied dose
    3.6 mg monthly · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Adverse events (AEs) were similar between treatment arms, except for more injection site reactions with degarelix versus goserelin.
    2 context sentences
    Summary · context
    This is an open-label, multi-centre study in which men aged ≥18 years were randomised in a 1:1 ratio to once-a-month subcutaneous injection of either degarelix (240/80 mg) or goserelin (3.6 mg) for 12 months.
    Summary · context
    Baseline demographics and disease characteristics were similar between degarelix (n=142) and goserelin (n=141) treatment arms.
  7. 07HumanRandomized controlled trialSafety outcome

    In Chinese men with prostate cancer, injection site reactions were more frequent with degarelix than goserelin.

    In plain wordsIn Chinese men with prostate cancer, injection site reactions were more frequent with degarelix than goserelin.

    Peptide
    Degarelix
    Outcome
    IncreaseInjection site reactions
    Study

    n = 283

    Comparator
    Goserelin
    Outcome group
    Adverse events · Skin and wound
    Studied dose
    240/80 mg monthly · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Adverse events (AEs) were similar between treatment arms, except for more injection site reactions with degarelix versus goserelin.
    2 context sentences
    Summary · context
    This is an open-label, multi-centre study in which men aged ≥18 years were randomised in a 1:1 ratio to once-a-month subcutaneous injection of either degarelix (240/80 mg) or goserelin (3.6 mg) for 12 months.
    Summary · context
    Baseline demographics and disease characteristics were similar between degarelix (n=142) and goserelin (n=141) treatment arms.
  8. 08HumanRandomized controlled trialSafety outcome

    In Chinese men with prostate cancer, injection site reactions were less frequent with goserelin than degarelix.

    In plain wordsIn Chinese men with prostate cancer, injection site reactions were less frequent with goserelin than degarelix.

    Peptide
    Goserelin
    Outcome
    DecreaseInjection site reactions
    Study

    n = 283

    Comparator
    Degarelix
    Outcome group
    Adverse events · Skin and wound
    Studied dose
    3.6 mg monthly · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Adverse events (AEs) were similar between treatment arms, except for more injection site reactions with degarelix versus goserelin.
    2 context sentences
    Summary · context
    This is an open-label, multi-centre study in which men aged ≥18 years were randomised in a 1:1 ratio to once-a-month subcutaneous injection of either degarelix (240/80 mg) or goserelin (3.6 mg) for 12 months.
    Summary · context
    Baseline demographics and disease characteristics were similar between degarelix (n=142) and goserelin (n=141) treatment arms.
  9. 09HumanRandomized controlled trialSafety outcome

    In Chinese men with prostate cancer, adverse events led to discontinuation in 2.8% receiving degarelix versus 6.4% receiving goserelin.

    In plain wordsAdverse events led to discontinuation in 2.8% with degarelix versus 6.4% with goserelin in Chinese men with prostate cancer.

    Peptide
    Degarelix
    Outcome
    DecreaseDiscontinuation due to adverse events
    Study

    n = 283

    Comparator
    Goserelin
    Outcome group
    Adverse events · Whole body
    Studied dose
    240/80 mg monthly · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    Discontinuations
    4 patients
    degarelix; 2.8%
    Discontinuations
    9 patients
    goserelin; 6.4%

    Source sentences

    Summary
    Four (2.8%) and nine (6.4%) patients discontinued due to AEs in degarelix and goserelin groups, respectively.
    2 context sentences
    Summary · context
    This is an open-label, multi-centre study in which men aged ≥18 years were randomised in a 1:1 ratio to once-a-month subcutaneous injection of either degarelix (240/80 mg) or goserelin (3.6 mg) for 12 months.
    Summary · context
    Baseline demographics and disease characteristics were similar between degarelix (n=142) and goserelin (n=141) treatment arms.
  10. 10HumanRandomized controlled trialSafety outcome

    In Chinese men with prostate cancer, adverse events led to discontinuation in 6.4% receiving goserelin versus 2.8% receiving degarelix.

    In plain wordsAdverse events led to discontinuation in 6.4% with goserelin versus 2.8% with degarelix in Chinese men with prostate cancer.

    Peptide
    Goserelin
    Outcome
    IncreaseDiscontinuation due to adverse events
    Study

    n = 283

    Comparator
    Degarelix
    Outcome group
    Adverse events · Whole body
    Studied dose
    3.6 mg monthly · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    Discontinuations
    9 patients
    goserelin; 6.4%
    Discontinuations
    4 patients
    degarelix; 2.8%

    Source sentences

    Summary
    Four (2.8%) and nine (6.4%) patients discontinued due to AEs in degarelix and goserelin groups, respectively.
    2 context sentences
    Summary · context
    This is an open-label, multi-centre study in which men aged ≥18 years were randomised in a 1:1 ratio to once-a-month subcutaneous injection of either degarelix (240/80 mg) or goserelin (3.6 mg) for 12 months.
    Summary · context
    Baseline demographics and disease characteristics were similar between degarelix (n=142) and goserelin (n=141) treatment arms.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:35 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.